Quest and Vermillion to launch OVA1 ovarian cancer test in India
This article was originally published in Clinica
Executive Summary
The co-developers of the OVA1 ovarian cancer blood test, Quest Diagnostics and Vermillion, are to launch the test in India, its first market outside the US. It should become available there in the second quarter. OVA1 is designed to determine whether a pelvic mass is malignant or benign in women who are about to undergo surgery. This could help determine which physician is most appropriate for removing the mass – gynaecologic oncologists are more experienced than regular gynaecologists at dealing with invasive, malignant tumours.